Updates are available Correction dated 2022-05-10
Click to view Correction: https://doi.org/10.1038/s41598-022-12074-y
-
Authors
Oviedo Flores, Krystell http://orcid.org/0000-0001-8096-3883
Kaltenegger, Lukas
Eibensteiner, Fabian http://orcid.org/0000-0001-5012-3082
Unterwurzacher, Markus
Kratochwill, Klaus http://orcid.org/0000-0003-0803-614X
Aufricht, Christoph http://orcid.org/0000-0002-0487-4296
König, Franz http://orcid.org/0000-0002-6893-3304
Vychytil, Andreas
-
Funding
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (812699)
Austrian Federal Ministry of Science, Research and Economy
National Foundation for Research, Technology and Development
- License Information
-
More Information
Article History
Received: 24 November 2021
Accepted: 21 March 2022
First Online: 5 April 2022
Change Date: 10 May 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-022-12074-y
Competing interests
: A.V. has received honoraria and travel grants from Baxter and Fresenius and consulting fees from Baxter unrelated to this study. C.A. is cofounder of Zytoprotec GmbH, a spin-off of the Medical University Vienna that holds the patent “Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue” (International Publication Number: WO 2008/106702 A1). M.U. and K.K. are former employees, K.K. is a consultant of Zytoprotec GmbH. K.O.F. is PhD candidate at the Medical University of Vienna and also employee of Baxter Healthcare GmbH, funded as early-stage researcher by the IMPROVE-PD (812699)/Horizon 2020 project. Baxter Healthcare did neither participate in the development of the protocol and study design, nor in the analysis of data or elaboration of the manuscript. All other authors have no conflicts of interest to declare.
